It is now about 20 years since the first case of a gain-of-function mutation involving the as-yet-
unknown actor in cholesterol homeostasis, proprotein convertase subtilisin/kexin type 9 …

Background Patients with severe hypertriglyceridaemia (sHTG) are often refractory to lipid‐
lowering therapy. Apolipoprotein (Apo) CIII inhibition could be promising to treat subjects …

Background: Endothelial dysfunction has a key role in the pathogenesis of coronavirus
disease 2019 (COVID-19) and its disabling complications. We designed a case-control …

Genetics of Familial Hypercholesterolemia (FH) is ascribable to pathogenic variants in
genes encoding proteins leading to an impaired LDL uptake by the LDL receptor (LDLR) …

International guidelines strongly recommend statins alone or in combination with other lipid-
lowering agents to lower low-density lipoprotein cholesterol (LDL-C) levels for patients with …

Background Treatment with protein convertase subtilisin kexin type 9 inhibitors (PCSK-9i)
reduced cholesterol levels and cardiovascular events in patients with hypercholesterolemia …

Background Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve endothelial
dysfunction and reduce cardiovascular events in individuals with type 2 diabetes (T2D) …

Acute Coronary Syndrome (ACS) remains one of the most frequent causes of morbidity and
mortality in the world. Although the age-and gender-adjusted incidence of ACS is …

Background and aims Familial hypercholesterolemia (FH) is an autosomal dominant
disease that leads to cardiovascular (CV) disease. Proprotein convertase subtilisin/kexin …

Compelling evidence supports the causative link between increased levels of low-density
lipoprotein cholesterol (LDL-C) and atherosclerotic cardiovascular disease (CVD) …